Search clinical trials for: Nemvaleukin Alfa Subcutaneous

Total 3787 results

Westfälische Wilhelms-Universität Münster
Chiesi GmbH

Recruiting

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa (GoPEG)

Fabry Disease

Germany
Taipei Veterans General Hospital, Taiwan

Not yet recruiting

Higher Dose of Alglucosidase Alpha for Pompe Disease

Glycogen Storage Disease Type II
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Nasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing Carinoma

Hong Kong
Amgen

Completed

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

Inflammatory Diseases

United Kingdom
University of Turin, Italy

Completed

Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF

Fertility Disorders

Italy
University Hospital Tuebingen
Joachim Riethmueller, Dr. med.

Unknown

Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa

Long Term Ventilation

Germany
University of Texas Southwestern Medical Center

Completed

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (SIMPLE)

Diabetes Mellitus, Type 2 | Diabetes

United States
Mayo Clinic

Terminated

Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure

Heart Failure

United States
United Allergy Services

Unknown

Corn Occupational Rhinitis SCIT Efficacy Study

Rhinitis
Sanofi

Recruiting

Avalglucosidase Alfa Pregnancy Study

Pregnancy | Pompe Disease

United States
PharmaEssentia

Recruiting

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Polycythemia Vera

United States, Canada
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (SIMPLIFY-DN)

Cystic Fibrosis

United States
Genzyme, a Sanofi Company

Approved for marketing

Alglucosidase Alfa Temporary Access Program (ATAP)

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)

United States
Kyowa Kirin Co., Ltd.

Completed

A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients

Anemia

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Cancer | Anemia

United States
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
Amgen

Completed

Heart Failure and Anemia

Heart Failure | Anemia
Amgen

Completed

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Lymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia
Amgen

Completed

Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

Anemia | Kidney Disease
AM-Pharma

Completed

Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia

Hypophosphatasia

Germany
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Extension Study of PRX-102 for up to 60 Months

Fabry Disease

United States, Spain, United Kingdom, Paraguay
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Amgen

Completed

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Kyowa Kirin Co., Ltd.

Completed

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Anemia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Anemia

United States
Amgen

Completed

Fixed Dose NESP Study in Subjects With CRI

Pre-Dialysis
Amgen

Completed

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Anemia
Amgen

Completed

Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects

Anemia
Vastra Gotaland Region
Göteborg University

Recruiting

Adaptive Mechanisms In GRown up ObeSity Study (AMIGROS) (AMIGROS)

Obesity | Type 2 Diabetes

Sweden
Groupe d'Etude Therapeutique des Affections Inflammatoires...
Takeda

Recruiting

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) (DOPER)

Inflammatory Bowel Diseases

France
Medical University of Warsaw

Not yet recruiting

Continuous Glycemia Monitoring in Perioperative Period in Patients Undergoing Total Knee or Hip Arthroplasty

Hyperglycemia | Diabetes Mellitus, Type 2 | Osteoarthritis, Knee | Osteoarthritis, Hip
Hospices Civils de Lyon

Completed

Adipose Tissue & Uremia (MODAIR)

Chronic Kidney Disease - Stage V

France
Takeda

Completed

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

Influenza Infection
Shanghai Zhongshan Hospital

Not yet recruiting

Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Myasthenia Gravis
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
Denali Therapeutics Inc.

Active, not recruiting

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Mucopolysaccharidosis II

United States, Netherlands, Canada, United Kingdom
Pfizer

Completed

A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

Gaucher Disease
Chiesi Farmaceutici S.p.A.
Chiesi USA, Inc.

Available

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Fabry Disease

United States
Alexion Pharmaceuticals

Withdrawn

Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease (REBUILD)

Hypophosphatasia
The University of Hong Kong

Not yet recruiting

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery (GLUMINS)

Myocardial Injury

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy

Fatigue | Unspecified Adult Solid Tumor, Protocol Specific
Parc de Salut Mar

Completed

Generation of Positive Biological Samples to Epoetin for Doping Control.

There Are no Conditions Under Study. Healthy Volunteers
Amgen

Completed

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Anemia | Chronic Kidney Disease

France, Italy, United Kingdom, Belgium, Hungary, Spain, Israel, Portugal, Bulgaria, Serbia, Poland, Romania, Greece, Australia, Denmark, Russian Federation, Slovakia, Germany, Latvia, Estonia, Slovenia, Czech Republic, Mexico

Search clinical trials for: Nemvaleukin Alfa Subcutaneous

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations